Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
|ClinicalTrials.gov Identifier: NCT00254735|
Recruitment Status : Completed
First Posted : November 17, 2005
Last Update Posted : December 18, 2007
|Condition or disease||Intervention/treatment||Phase|
|Obsessive Compulsive Disorder||Drug: quetiapine fumarate Drug: SSRI/Clomipramine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||44 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study|
|Study Start Date :||April 2002|
|Study Completion Date :||March 2006|
- Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.
- Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.
- Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00254735
|Study Director:||AstraZeneca Germany Medical Director, MD||AstraZeneca|